1133-P: Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge Type 2 Diabetes Patients-An Exploratory Study

Post-hospital discharge (PHD) can be a challenging time for health care providers (HCPs) and patients. We analyzed use of Dexcom G6 CGMs in PHD T2D patient management. This study analyzed 30 days of PHD remote monitoring data for 28 T2D patients. Hospital discharge summaries and telehealth notes were analyzed for details around hospital stay, PHD outcomes, and patient-HCP interactions. Study sample was categorized into 3 cohorts to reflect disease severity and risk of mortality during hospitalization- Group A (Organ Transplants), Group B (High Severity), Group C (Medium Severity) (Table). Overall, Group B was the youngest (median (IQR): 37 years (37,55)) vs. Groups A & C (54 (47,59) & 55 (50,57)), had the shortest hospital stay (3 days (2,5)) vs. Groups A & C (8 (8,10) & 11 (7,15)) and the shortest diabetes duration (7 years (1,20) vs. Groups A & C (15 (2,27) & 10 (6,17)). Group A had the most telehealth encounters (20 (9,21) vs. Groups B & C (12 (11,15) & 12 (10,13)). Telehealth encounter notes detailed HCP interactions with CGM data including response to Dexcom Follow alerts, insulin titration, and diabetes self-care coaching. Using CGM, groups A & B showed decreased mean glucose and frequency of severe hypo- and hyper-glycemic events over the study period (Table). These early findings demonstrate the value of CGM to inform critical therapy adjustments for optimizing outcomes during PHD.